A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 47, Issue 3, 2005, Pages 413-419

  Gillenwater, Heidi H ^a   Stinchcombe, Thomas E ^b   Qaqish, Bahjat F ^b   Tyann, Maureen ^b   Hensing, Thomas A ^c   Socinski, Mark A ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c EVANSTON HOSPITAL   (United States)

Author keywords

Constant rate of infusion; Gemcitabine; Non small cell lung cancer; Paclitaxel

Indexed keywords

GEMCITABINE; PACLITAXEL; STEROID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEHYDRATION; DIARRHEA; DISEASE EXACERBATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; OBSERVATION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SOMATOSENSORY DISORDER; SURVIVAL RATE; TASK PERFORMANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 13844271670     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.08.009     Document Type: Article

References (17)

1. A. Jemal, R.C. Tiwari, and T. Murray Cancer statistics, 2004 54 1 2004 8 29
2. D.C. Ihde, and J.D. Minna Non-small cell lung cancer. Part I: Biology, diagnosis, and staging Curr Probl Cancer 15 2 1991 61 104
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311(7010):899-909.
4. K.S. Albain, J.J. Crowley, M. LeBlanc, and R.B. Livingston Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience J Clin Oncol 9 9 1991 1618 1626
5. J.L. Abbruzzese, R. Grunewald, and E.A. Weeks A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 9 3 1991 491 498
6. R. Grunewald, H. Kantarjian, M. Du, K. Faucher, P. Tarassoff, and W. Plunkett Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study J Clin Oncol 10 3 1992 406 413
7. M. Tempero, W. Plunkett, and V. Ruiz Van Haperen Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 18 2003 3402 3408
8. G. Giaccone, E.F. Smit, and J.P. van Meerbeeck A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients Ann Oncol 11 1 2000 109 112
9. M.L. Rothenberg, A. Sharma, and G.R. Weiss Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors Ann Oncol 9 7 1998 733 738
10. L.H. Einhorn, D. Raghaven, and H. Kindler A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors Proc Am Soc Clin Oncol 17 1998 207a
11. S.S. Shord, S.R. Faucette, and H.H. Gillenwater Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer Cancer Chemother Pharmacol 51 4 2003 328 336
12. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 1989 1 10
13. P. Kosmidis, N. Mylonakis, and C. Nicolaides Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial J Clin Oncol 20 17 2002 3578 3585
14. E.F. Smit, J.P. van Meerbeeck, and P. Lianes Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975 J Clin Oncol 21 21 2003 3909 3917
15. D. Isla, R. Rosell, and J.J. Sanchez Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 19 4 2001 1071 1077
16. Y.M. Chen, R.P. Perng, and Y.C. Lee Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated Ann Oncol 13 1 2002 108 115
17. V. Hirsh, R. Whittom, and L. Ofiara Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial Cancer 97 9 2003 2242 2247